
John M. Hoffmann
Examiner (ID: 5190, Phone: (571)272-1191 , Office: P/1741 )
| Most Active Art Unit | 1731 |
| Art Unit(s) | 1712, 1731, 1741, 1791, 1304, 1303 |
| Total Applications | 1565 |
| Issued Applications | 722 |
| Pending Applications | 142 |
| Abandoned Applications | 703 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17443816
[patent_doc_number] => 20220064321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => ANTI-CD20 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/531011
[patent_app_country] => US
[patent_app_date] => 2021-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9818
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531011
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/531011 | Anti-CD20 antibody | Nov 18, 2021 | Issued |
Array
(
[id] => 17687770
[patent_doc_number] => 20220195062
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => DOSING REGIMEN OF COMBINATION OF ANTICD20 AND ANTI-BLYS ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/519063
[patent_app_country] => US
[patent_app_date] => 2021-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5601
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519063
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/519063 | Dosing regimen of combination of ANTICD20 and anti-BlyS antibodies | Nov 3, 2021 | Issued |
Array
(
[id] => 17546727
[patent_doc_number] => 20220118068
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => Modulation of Proprotein Convertase Subtilisin/Kexin 9 Expression (PCSK9) with HSP 27 and/or HSP25
[patent_app_type] => utility
[patent_app_number] => 17/515001
[patent_app_country] => US
[patent_app_date] => 2021-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15395
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17515001
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/515001 | Modulation of proprotein convertase subtilisin/kexin 9 expression (PCSK9) with HSP 27 and/or HSP25 | Oct 28, 2021 | Issued |
Array
(
[id] => 17595396
[patent_doc_number] => 20220144969
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => METHODS FOR REDUCING CARDIOVASCULAR RISK
[patent_app_type] => utility
[patent_app_number] => 17/504921
[patent_app_country] => US
[patent_app_date] => 2021-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19959
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504921
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/504921 | METHODS FOR REDUCING CARDIOVASCULAR RISK | Oct 18, 2021 | Abandoned |
Array
(
[id] => 17642011
[patent_doc_number] => 20220169749
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR PREVENTING HEREDITARY ANGIOEDEMA ATTACK
[patent_app_type] => utility
[patent_app_number] => 17/500214
[patent_app_country] => US
[patent_app_date] => 2021-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17500214
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/500214 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR PREVENTING HEREDITARY ANGIOEDEMA ATTACK | Oct 12, 2021 | Pending |
Array
(
[id] => 17473984
[patent_doc_number] => 20220081488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-17
[patent_title] => REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB
[patent_app_type] => utility
[patent_app_number] => 17/495559
[patent_app_country] => US
[patent_app_date] => 2021-10-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8334
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17495559
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/495559 | REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB | Oct 5, 2021 | Abandoned |
Array
(
[id] => 17368331
[patent_doc_number] => 20220023383
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => PHARMACEUTICAL COMPOSITIONS AND METHODS TARGETING WNT PATHWAY PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/493896
[patent_app_country] => US
[patent_app_date] => 2021-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20616
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493896
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/493896 | Pharmaceutical compositions and methods targeting Wnt pathway proteins | Oct 4, 2021 | Issued |
Array
(
[id] => 17672716
[patent_doc_number] => 20220185883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3
[patent_app_type] => utility
[patent_app_number] => 17/484794
[patent_app_country] => US
[patent_app_date] => 2021-09-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 78635
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17484794
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/484794 | METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 | Sep 23, 2021 | Abandoned |
Array
(
[id] => 18739619
[patent_doc_number] => 20230348578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/021912
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52759
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021912
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/021912 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF | Sep 1, 2021 | Pending |
Array
(
[id] => 18964213
[patent_doc_number] => 11897964
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-13
[patent_title] => Anti-PSGL-1 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/460883
[patent_app_country] => US
[patent_app_date] => 2021-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 21264
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17460883
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/460883 | Anti-PSGL-1 antibodies and uses thereof | Aug 29, 2021 | Issued |
Array
(
[id] => 19265390
[patent_doc_number] => 20240209089
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => CD8 BINDING POLYPEPTIDE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/017236
[patent_app_country] => US
[patent_app_date] => 2021-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017236
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017236 | CD8 BINDING POLYPEPTIDE AND USE THEREOF | Jul 19, 2021 | Pending |
Array
(
[id] => 20336550
[patent_doc_number] => 20250340670
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-11-06
[patent_title] => ANTIBODY SPECIFICALLY BINDING TO PTK7 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/016100
[patent_app_country] => US
[patent_app_date] => 2021-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016100
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/016100 | Antibody specifically binding to PTK7 and use thereof | Jul 15, 2021 | Issued |
Array
(
[id] => 18157953
[patent_doc_number] => 20230024543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-26
[patent_title] => METHODS OF TREATING ANAEMIA
[patent_app_type] => utility
[patent_app_number] => 17/370446
[patent_app_country] => US
[patent_app_date] => 2021-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 220629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 173
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17370446
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/370446 | METHODS OF TREATING ANAEMIA | Jul 7, 2021 | Abandoned |
Array
(
[id] => 18656079
[patent_doc_number] => 20230301950
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => METHOD FOR SELECTING CANCER PATIENTS FOR WHOM COMBINATION THERAPY WITH RETINOID AND CANCER THERAPEUTIC AGENT IS EFFECTIVE, AND COMBINATION MEDICAMENT WITH RETINOID AND CANCER THERAPEUTIC AGENT
[patent_app_type] => utility
[patent_app_number] => 18/010686
[patent_app_country] => US
[patent_app_date] => 2021-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15017
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010686
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/010686 | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent | Jun 27, 2021 | Issued |
Array
(
[id] => 18610907
[patent_doc_number] => 20230277637
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => METHOD FOR THE TREATMENT OF A VIRAL INFECTION WITH HUMAN ALPHA-1 ANTITRYPSIN
[patent_app_type] => utility
[patent_app_number] => 17/999362
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999362
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999362 | METHOD FOR THE TREATMENT OF A VIRAL INFECTION WITH HUMAN ALPHA-1 ANTITRYPSIN | May 25, 2021 | Pending |
Array
(
[id] => 18931099
[patent_doc_number] => 11883493
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-30
[patent_title] => Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
[patent_app_type] => utility
[patent_app_number] => 17/241628
[patent_app_country] => US
[patent_app_date] => 2021-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 93
[patent_figures_cnt] => 98
[patent_no_of_words] => 105545
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17241628
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/241628 | Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders | Apr 26, 2021 | Issued |
Array
(
[id] => 19738352
[patent_doc_number] => 12215170
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-04
[patent_title] => Anti-TMPRSS6 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/916008
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 93
[patent_no_of_words] => 17829
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916008
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/916008 | Anti-TMPRSS6 antibodies and uses thereof | Apr 4, 2021 | Issued |
Array
(
[id] => 18420213
[patent_doc_number] => 20230174674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME
[patent_app_type] => utility
[patent_app_number] => 17/916621
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23709
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -102
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916621
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/916621 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME | Apr 1, 2021 | Pending |
Array
(
[id] => 17214521
[patent_doc_number] => 20210347858
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS
[patent_app_type] => utility
[patent_app_number] => 17/221515
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -72
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221515
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/221515 | ALIMENTARY AND SYSTEMIC ANTIVIRAL THERAPEUTICS | Apr 1, 2021 | Abandoned |
Array
(
[id] => 17185261
[patent_doc_number] => 20210332146
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => ANTI-CD20 GLYCOANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/211619
[patent_app_country] => US
[patent_app_date] => 2021-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23247
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17211619
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/211619 | Anti-CD20 glycoantibodies and uses thereof | Mar 23, 2021 | Issued |